Printer Friendly

Artificial pancreas safe, effective in early study.

An artificial pancreas designed to deliver insulin to diabetic patients without the need for injections has been found safe and effective in a preliminary 6-month study involving 10 patients, an international team reported at the American Diabetes Association annual meeting held in June in San Francisco, CA.

Eric Renard, MD and colleagues at Lapeyronie Hospital in Montpelier, France working with investigators at Medtronic MiniMed of Northridge, CA tested the artificial pancreas in type 1 (insulin-dependent) diabetics with relatively stable disease. The device consists of an insulin reservoir implanted in the tissue lining the abdominal cavity and connected to a sensor implanted in the jugular vein in the neck. When the sensor detects an increase in blood glucose, the reservoir delivers the required amount of the sugar-regulating hormone. The reservoir requires insulin refills every month or so.

Because of the accuracy of the sensor, which measures glucose levels as many as 288 times during a 24-hour period, Renard said that blood glucose levels were controlled more than 60% of the time in the test patients, compared with 25% of the time in patients using injectable insulin.
COPYRIGHT 2002 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Artificial pancreas safe, effective in early study.
Publication:Transplant News
Geographic Code:0JINT
Date:Jun 30, 2002
Words:185
Previous Article:Two researchers charged with theft of genes that showed promise in creating new transplant drugs.
Next Article:New studies bolster promise of both adult and embryonic stem cells.
Topics:


Related Articles
Medicare finally to pay for pancreas transplants done simultaneously with, after renal transplants.
Blood vessels (sans blood) shape organs.
Clinical trial of artificial pancreas to start next month in UK.
NOBEX REPORTS ORAL INSULIN CLINICAL TRIAL PROMISING.
Diabetics receiving pancreas transplants have slightly lower survival rates than those on conventional therapy.
For diabetics, insulin transplants increasingly an option.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |